Abstract
Objective: We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL). Methods: Forty-one HIV-negative patients (18-70 years; Eastern Cooperative Oncology Group performance status ≤3) with histologically confirmed PCNSL received 3 courses of MATILDE chemotherapy followed by whole-brain radiotherapy (WBRT). Chemotherapy activity was the primary endpoint. Results: Overall response rate was 76% (95% confidence interval [CI] 63%-89%) after chemotherapy and 83% (95% CI 71%-95%) after chemotherapy ± radiotherapy. At a median follow-up of 144 months (range 47-153), 31 patients experienced an event: relapse in 24, progressive disease in 3, and toxic death in 4, with a 5-year progression-free survival of 24% ± 8%. Two patients experienced a late relapse (100 and 101 months). Nine patients are alive and disease-free, 8 of whom are alive at >10 years, with a 5-year overall survival of 30% ± 7%. At 10 years from diagnosis, no patient showed chronic hematologic and nonhematologic toxicities, with a Mini-Mental State Examination score of ≥29 in all cases but one. Conclusions: At a median follow-up of 12 years, MATILDE regimen followed by WBRT confirmed the previously reported survival plateau, which further proves its long-lasting efficacy with acceptable neurologic deficits. Classification of evidence: This study provides Class IV evidence that in patients with PCNSL, MATILDE chemotherapy followed by response-tailored radiotherapy increases the probability of disease remission at 12 years.
| Original language | English |
|---|---|
| Pages (from-to) | 1370-1373 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 82 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - Apr 15 2014 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Arts and Humanities (miscellaneous)
Cite this
MATILDE chemotherapy regimen for primary CNS lymphoma : Results at a median follow-up of 12 years. / Ferreri, Andrés J M; Ciceri, Fabio; Brandes, Alba A.; Montanari, Mauro; Balzarotti, Monica; Spina, Michele; Ilariucci, Fiorella; Zaja, Francesco; Stelitano, Caterina; Bobbio, Flavio; Corazzelli, Gaetano; Baldini, Luca; Reni, Michele.
In: Neurology, Vol. 82, No. 15, 15.04.2014, p. 1370-1373.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MATILDE chemotherapy regimen for primary CNS lymphoma
T2 - Results at a median follow-up of 12 years
AU - Ferreri, Andrés J M
AU - Ciceri, Fabio
AU - Brandes, Alba A.
AU - Montanari, Mauro
AU - Balzarotti, Monica
AU - Spina, Michele
AU - Ilariucci, Fiorella
AU - Zaja, Francesco
AU - Stelitano, Caterina
AU - Bobbio, Flavio
AU - Corazzelli, Gaetano
AU - Baldini, Luca
AU - Reni, Michele
PY - 2014/4/15
Y1 - 2014/4/15
N2 - Objective: We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL). Methods: Forty-one HIV-negative patients (18-70 years; Eastern Cooperative Oncology Group performance status ≤3) with histologically confirmed PCNSL received 3 courses of MATILDE chemotherapy followed by whole-brain radiotherapy (WBRT). Chemotherapy activity was the primary endpoint. Results: Overall response rate was 76% (95% confidence interval [CI] 63%-89%) after chemotherapy and 83% (95% CI 71%-95%) after chemotherapy ± radiotherapy. At a median follow-up of 144 months (range 47-153), 31 patients experienced an event: relapse in 24, progressive disease in 3, and toxic death in 4, with a 5-year progression-free survival of 24% ± 8%. Two patients experienced a late relapse (100 and 101 months). Nine patients are alive and disease-free, 8 of whom are alive at >10 years, with a 5-year overall survival of 30% ± 7%. At 10 years from diagnosis, no patient showed chronic hematologic and nonhematologic toxicities, with a Mini-Mental State Examination score of ≥29 in all cases but one. Conclusions: At a median follow-up of 12 years, MATILDE regimen followed by WBRT confirmed the previously reported survival plateau, which further proves its long-lasting efficacy with acceptable neurologic deficits. Classification of evidence: This study provides Class IV evidence that in patients with PCNSL, MATILDE chemotherapy followed by response-tailored radiotherapy increases the probability of disease remission at 12 years.
AB - Objective: We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL). Methods: Forty-one HIV-negative patients (18-70 years; Eastern Cooperative Oncology Group performance status ≤3) with histologically confirmed PCNSL received 3 courses of MATILDE chemotherapy followed by whole-brain radiotherapy (WBRT). Chemotherapy activity was the primary endpoint. Results: Overall response rate was 76% (95% confidence interval [CI] 63%-89%) after chemotherapy and 83% (95% CI 71%-95%) after chemotherapy ± radiotherapy. At a median follow-up of 144 months (range 47-153), 31 patients experienced an event: relapse in 24, progressive disease in 3, and toxic death in 4, with a 5-year progression-free survival of 24% ± 8%. Two patients experienced a late relapse (100 and 101 months). Nine patients are alive and disease-free, 8 of whom are alive at >10 years, with a 5-year overall survival of 30% ± 7%. At 10 years from diagnosis, no patient showed chronic hematologic and nonhematologic toxicities, with a Mini-Mental State Examination score of ≥29 in all cases but one. Conclusions: At a median follow-up of 12 years, MATILDE regimen followed by WBRT confirmed the previously reported survival plateau, which further proves its long-lasting efficacy with acceptable neurologic deficits. Classification of evidence: This study provides Class IV evidence that in patients with PCNSL, MATILDE chemotherapy followed by response-tailored radiotherapy increases the probability of disease remission at 12 years.
UR - http://www.scopus.com/inward/record.url?scp=84902131983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902131983&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000000314
DO - 10.1212/WNL.0000000000000314
M3 - Article
C2 - 24634458
AN - SCOPUS:84902131983
VL - 82
SP - 1370
EP - 1373
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 15
ER -